IFAP Syndrome 2 (SREBF1-Associated Autosomal-Dominant IFAP Syndrome): Comprehensive Research Report

1. Disease Information

Overview. IFAP syndrome 2 (IFAP2) is one of two known genetic forms of Ichthyosis Follicularis, Atrichia, and Photophobia (IFAP) syndrome, a rare ectodermal dysplasia/syndromic ichthyosis characterized by the classic triad of non-inflammatory follicular hyperkeratosis (ichthyosis follicularis), congenital or near-congenital hair loss (atrichia/hypotrichosis), and photophobia with corneal disease. Unlike the originally described X-linked form (IFAP syndrome 1, caused by MBTPS2 mutations), IFAP2 is autosomal dominant, caused by heterozygous, largely de novo missense/small in-frame deletion variants in SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1), reported in 2020 by Wang et al. (PMID: 32497488) — "Mutations in SREBF1, Encoding Sterol Regulatory Element Binding Transcription Factor 1, Cause Autosomal-Dominant IFAP Syndrome," American Journal of Human Genetics.

Key identifiers: - OMIM: #619016 — IFAP SYNDROME 2; IFAP2 (gene: SREBF1, 184756, chr 17p11.2) - MONDO: MONDO:0100221 (IFAP syndrome 2); parent term MONDO:0100212 (IFAP syndrome, general) - Orphanet: ORPHA2273 (IFAP syndrome, umbrella entry covering both molecular subtypes) - MedGen: C5436607 - GTR: C5436607 - Distinguish from IFAP syndrome 1 (OMIM #308205, X-linked, MBTPS2) and BRESHECK syndrome (a severe MBTPS2-allelic disorder with additional CNS/skeletal/genital anomalies)

Synonyms: Ichthyosis follicularis–atrichia–photophobia syndrome, type 2; autosomal-dominant IFAP syndrome; SREBF1-related IFAP syndrome.

Evidence basis: This is aggregated disease-level knowledge derived from a founding molecular-genetics cohort study (11 unrelated individuals, 2 families + 9 simplex cases) plus subsequent single-patient/small case-series reports — not large-scale EHR/registry data, reflecting the extreme rarity of the condition (well under 100 reported IFAP2 cases worldwide as of 2025).

2. Etiology

Causal factor: Purely monogenic/genetic. Heterozygous missense substitutions or small in-frame deletions in SREBF1 disrupt site-1-protease (S1P) recognition and cleavage of the SREBP1 transcription factor, producing a dominant loss-of-function/dominant-negative effect on SREBP-target lipogenic and keratinization gene programs (PMID: 32497488).

Genetic risk factors: - Virtually all reported pathogenic variants cluster in a 4-residue hotspot (residues 527–530) forming the arginine-X-X-leucine (RXXL) S1P recognition motif of SREBP1: - c.1579C>T, p.Arg527Cys — the dominant recurrent variant, found in 9 of 11 individuals (82%) in the founding cohort, arising independently (mostly de novo, confirmed segregating in two families) - c.1582_1584del, p.Asn528del — 2/11 individuals, segregated in Family 1 - c.1589T>C, p.Leu530Pro — 1/11 individuals, confirmed de novo - Additional variants reported subsequently: p.Arg557Cys (chr17:17720597G>A, Ambarchyan et al. 2024, de novo, confirmed absent in both parents) and c.1670G>A (associated with an atypical phenotype lacking photophobia; Zhu et al., PMID: 39912473) - All founding-cohort variants were absent from gnomAD and ExAC, and the key residues (Arg527, Leu530) are highly conserved across species — consistent with pathogenicity (PMID: 32497488). - Inheritance: Autosomal dominant, predominantly arising as de novo mutations in simplex cases, though vertical transmission was documented within two multigenerational families in the founding study (mother-daughter pairs, both surviving to adulthood, indicating compatibility with reproduction and non-lethality of the heterozygous state).

Environmental/other risk factors: None identified — no epidemiological or toxin/exposure association has been reported; this is a purely Mendelian condition.

Protective factors: None reported in the literature.

Gene-environment interactions: Not established; disease expression appears driven by the germline variant itself rather than by environmental modifiers, though phenotypic severity (e.g., presence/absence of photophobia, degree of skin plaque involvement) varies even among carriers of the same recurrent variant (p.Arg527Cys), suggesting stochastic or unidentified modifying factors.

3. Phenotypes

Phenotype data below are drawn from the founding 11-patient cohort (PMID: 32497488) and subsequent case reports (Ambarchyan et al. 2024; Zhu et al. 2025, PMID: 39912473; Zhu et al. 2025 meibum study, PMID: 40778116).

Cutaneous

Hair

Ocular (near-universal and often the most functionally disabling feature)

Onset, severity, progression

• Onset: Ichthyosis follicularis, photophobia, and atrichia manifest soon after birth; cataract, meibomian gland dysfunction, and hyperkeratotic plaques emerge during early childhood.
• Severity/progression: Variable — generally chronic and slowly progressive for skin and hair; ocular disease can progress to significant visual impairment without aggressive management. Severity does not correlate simply with genotype (identical p.Arg527Cys variant produces a range of severities; the c.1670G>A variant produces an atypical, milder-appearing but psoriasiform phenotype without photophobia).
• Quality of life impact: Photophobia and progressive corneal disease are frequently the most disabling features; chronic skin hyperkeratosis and alopecia carry psychosocial burden. No formal EQ-5D/SF-36 disease-specific QOL studies were identified in the literature (data gap).

4. Genetic/Molecular Information

• Causal gene: SREBF1 (HGNC:11289; OMIM 184756), chromosome 17p11.2, encoding sterol regulatory element-binding protein 1 (SREBP1), a basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factor with two isoforms (SREBP-1a and SREBP-1c) generated by alternative promoter usage.
• Variant classification: All reported IFAP2 variants are missense substitutions or small in-frame deletions, clustering within a 4-amino-acid hotspot (residues 527–530) that forms the RXXL recognition motif required for site-1-protease (S1P) cleavage. Under ACMG/AMP criteria these would be classified pathogenic/likely pathogenic based on de novo occurrence, absence from gnomAD/ExAC, cross-species conservation, and confirmatory functional data.
• Allele frequency: Not present in gnomAD, ExAC, or 1000 Genomes — consistent with a highly penetrant, reproductively compatible but rare dominant disorder maintained largely by recurrent de novo mutation.
• Functional consequences (from PMID: 32497488):
• In sterol-free (activating) conditions, wild-type SREBP1 is cleaved by S1P then S2P in the Golgi, releasing a 71-kD transcriptionally active nuclear fragment.
• Transfection of HEK293 cells with the p.Arg527Cys, p.Asn528del, or p.Leu530Pro variants abolished detection of the 71-kD cleaved nuclear fragment.
• Immunofluorescence showed impaired nuclear translocation — mutant SREBP1 signal remained cytoplasmic rather than nuclear.
• SRE-luciferase reporter assays showed markedly reduced transcriptional activity for mutant vs. wild-type SREBP1: reduced to 33% (p.Arg527Cys), 41% (p.Asn528del), 28% (p.Leu530Pro), and 47% (p.Arg527Ala) of wild-type activity.
• Mechanistically this is a loss-of-function/dominant-negative effect on S1P-mediated proteolytic activation (functional_impact_category candidates: LOSS_OF_FUNCTION or DOMINANT_NEGATIVE).
• Downstream transcriptomic effects (RNA-seq, scalp skin, 4 affected individuals vs. controls): 72 significantly differentially expressed genes (FDR<0.05), including:
• LDLR (low-density lipoprotein receptor) — significantly downregulated in all affected individuals (classic SREBP target)
• SCD (stearoyl-CoA desaturase, sebaceous-gland-enriched) — markedly reduced
• KRT6A, KRT6C, KRT16 (outer root sheath keratins) — significantly reduced
• Gene-set enrichment: keratin filament, keratinization, intermediate filament cytoskeleton, epidermal cell differentiation, skin development, cornification pathways
• Modifier genes: None established.
• Epigenetic information: No disease-specific epigenetic (methylation/histone) studies identified — data gap.
• Chromosomal abnormalities: None reported; IFAP2 is caused by point mutation/small indel, not large structural variation.

Suggested ontology terms: HGNC:11289 (SREBF1); GO:0032933 (SREBP signaling pathway); GO:0016126 (sterol biosynthetic process); GO:0006695 (cholesterol biosynthetic process); GO:0045543 (regulation of fatty acid biosynthetic process).

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors have been identified or reported for IFAP2 — it is a purely germline monogenic disorder. No gene-environment interaction data exist.

6. Mechanism / Pathophysiology

Ordered causal chain:

1. A heterozygous missense variant or small in-frame deletion in SREBF1 (residues 527–530, or occasionally elsewhere, e.g., p.Arg557Cys, c.1670G>A) disrupts the RXXL motif required for site-1-protease (S1P) recognition of the SREBP1 precursor protein → leads to failure of proteolytic cleavage of SREBP1 in the Golgi.
2. Failure of S1P (and consequently S2P) cleavage results in retention of SREBP1 in an inactive, membrane-tethered/cytoplasmic form and loss of the transcriptionally active nuclear bHLH-Zip fragment (demonstrated directly by immunoblot/immunofluorescence in transfected cells) — this is a dominant-negative/loss-of-function mechanism, since one mutant allele suppresses net SREBP1 transcriptional output even in the presence of a normal allele.
3. Reduced nuclear SREBP1 activity leads to transcriptional downregulation of SREBP-target lipogenic genes (demonstrated by SRE-luciferase reporter assays showing 28–47% residual activity, and by RNA-seq showing reduced LDLR and SCD expression in patient scalp skin) → impaired cholesterol/fatty-acid biosynthesis in skin, hair follicle, and meibomian gland tissue.
4. Impaired lipogenesis in sebaceous/meibomian glands results in abnormal meibum lipid composition (directly documented by lipidomic analysis, PMID: 40778116), driving meibomian gland dysfunction, ocular surface lipid-layer instability, tear-film disruption, and consequent photophobia, punctate keratopathy, corneal pannus, and (via a less well-defined pathway involving chronic ocular surface inflammation) cataract formation.
5. In parallel, disrupted SREBP1 signaling in the epidermis and hair follicle leads to reduced expression of outer-root-sheath keratins (KRT6A, KRT6C, KRT16) and dysregulated epidermal differentiation/cornification gene programs → follicular hyperkeratosis (ichthyosis follicularis) and structurally abnormal hair shafts (trichorrhexis nodosa, seen on SEM as cuticle warping/detachment), resulting in hair fragility and atrichia/hypotrichosis.
6. Independently, disrupted lipid/sterol homeostasis in keratinocytes is associated with increased in situ keratinocyte apoptosis (demonstrated by TUNEL staining of patient scalp biopsies vs. controls), which the authors propose as an additional contributor to hyperkeratosis and hypotrichosis (this apoptosis-mediation step is explicitly noted by the authors as inferred/associative rather than mechanistically fully demonstrated).
7. In a subset of patients carrying particular variants (e.g., c.1670G>A), reduced nuclear SREBP1 translocation in lesional skin is instead associated with enhanced IL-17A/S100A8 staining, suggesting a branch toward a psoriasiform inflammatory phenotype rather than (or in addition to) classic follicular ichthyosis — this branch and its relationship to the canonical lipogenic-deficiency mechanism above is not yet fully resolved and represents a knowledge gap.

Molecular pathways: SREBP/SCAP/Insig sterol-sensing pathway (KEGG/Reactome: SREBP signaling); under sterol-replete conditions SCAP-SREBP is retained in the ER by Insig; upon sterol depletion, the SCAP-SREBP complex traffics via COPII vesicles to the Golgi where sequential S1P then S2P cleavage releases the active nuclear transcription factor — the step disrupted in IFAP2 is the S1P cleavage step (the analogous S2P step is disrupted in X-linked IFAP1/MBTPS2, making IFAP1 and IFAP2 mechanistically parallel/convergent disorders of the same proteolytic cascade).

Cellular processes: epidermal differentiation, cornification, hair follicle keratinization, sebocyte/meibocyte lipogenesis, keratinocyte apoptosis.

Protein dysfunction: SREBP1 loss-of-function via blocked intramembrane proteolysis (a "regulated intramembrane proteolysis," RIP, defect), analogous mechanistically to MBTPS2-related IFAP1/BRESHECK/keratosis follicularis spinulosa decalvans.

Tissue damage mechanisms: lipid-deficiency-driven barrier dysfunction (skin, meibomian gland), chronic follicular keratin plugging, oxidative/apoptotic keratinocyte stress.

Suggested GO terms: GO:0032933 (SREBP signaling pathway); GO:0006694 (steroid biosynthetic process); GO:0044255 (cellular lipid metabolic process); GO:0031424 (keratinization); GO:0008544 (epidermis development); GO:0006915 (apoptotic process). Suggested CL terms: CL:0000312 (keratinocyte); CL:1000428 (outer root sheath cell of hair follicle, if available) or hair follicle-associated keratinocyte; CL:0002261 (sebaceous gland cell, for meibocyte-analog reasoning).

7. Anatomical Structures Affected

• Organ level (primary): Skin (epidermis, hair follicle, sebaceous apparatus) and eye (cornea, conjunctiva, meibomian glands, lens).
• Secondary: Nails (dystrophy); oral commissures (angular cheilitis).
• Body systems: Integumentary system (primary); ocular/visual system (primary); no cardiovascular, renal, or CNS involvement has been reported in IFAP2 (in contrast to MBTPS2-related BRESHECK syndrome, which does involve additional systems).
• Tissue/cell level: Follicular infundibular epithelium (keratotic plugging), outer root sheath keratinocytes, meibomian gland acinar cells, corneal epithelium, lens epithelium (cataract).
• Subcellular: Golgi apparatus (site of defective S1P cleavage) and nucleus (failure of SREBP1 translocation) — GO Cellular Component: GO:0005794 (Golgi apparatus), GO:0005634 (nucleus), GO:0005783 (endoplasmic reticulum, site of SCAP-SREBP1 pre-processing).
• Localization/laterality: Bilateral and symmetric for both cutaneous and ocular disease; the reported psoriasiform-variant plaques were bilateral but localized to extensor lower limbs.

Suggested UBERON terms: UBERON:0001003 (skin epidermis); UBERON:0002073 (hair follicle); UBERON:0006238 (meibomian gland); UBERON:0000964 (cornea); UBERON:0000965 (lens of camera-type eye).

8. Temporal Development

• Onset: Congenital/perinatal for the core triad (follicular ichthyosis, photophobia, atrichia); early childhood for cataract, meibomian gland dysfunction, and hyperkeratotic plaques.
• Onset pattern: Insidious/congenital rather than acute.
• Progression: Chronic, generally slowly progressive; ocular disease (corneal pannus, opacification) can progress toward significant visual impairment if unmanaged. No formal staging system exists.
• Disease course: Persistent/lifelong — documented survival to adulthood (mothers aged 47–48 years in the founding cohort still affected and able to have transmitted the condition to their daughters), indicating a non-lethal, chronic course, distinct from the more severe MBTPS2-BRESHECK spectrum.
• Remission: No spontaneous remission reported; symptomatic treatments (below) can partially stabilize cutaneous and corneal manifestations but do not resolve the underlying process.
• Critical periods: Early childhood ocular surveillance is critical given progression to cataract and corneal pannus if unmanaged.

9. Inheritance and Population

• Epidemiology: IFAP syndrome overall (both molecular subtypes combined) is exceedingly rare, with the literature describing well under 100 total published cases; IFAP2 specifically has been confirmed in a total of roughly 11–15+ published individuals across the founding cohort and subsequent case reports (2020–2025). No formal prevalence/incidence estimate (per 100,000) exists in Orphanet or GBD-type registries — data gap; prevalence_class would be best coded ULTRA_RARE/NOT_YET_DOCUMENTED.
• Inheritance pattern: Autosomal dominant.
• Penetrance: Appears complete/high in reported cases (all carriers manifest the core phenotype), though expressivity is markedly variable (e.g., presence/absence of photophobia, psoriasiform vs. classic follicular ichthyosis presentation).
• Expressivity: Variable, even for the identical recurrent p.Arg527Cys variant.
• Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not specifically documented but plausible given the de novo mutation pattern typical of dominant disorders with this mutational mechanism; not directly studied.
• Founder effects: None — the founding cohort spanned Chinese, Indian, European (German, Italian, Austrian), Congolese, and African American individuals, with the p.Arg527Cys variant recurring independently across these diverse backgrounds, consistent with mutational hotspot recurrence rather than a shared ancestral founder haplotype.
• Consanguinity: Not implicated (dominant, not recessive, disorder).
• Sex ratio: The founding cohort's two multiplex families were mother-daughter pairs (both affected members female in each family), but simplex cases spanned both sexes; no formal male:female ratio has been established, and there is no known biological basis (e.g., X-linkage) for a sex skew in this autosomal dominant disorder.
• Age distribution: Cohort ages ranged 3–48 years at time of reporting, consistent with lifelong persistence from infancy into adulthood.

10. Diagnostics

• Clinical criteria: Recognition of the classic triad — congenital follicular ichthyosis, atrichia/hypotrichosis, and photophobia — should prompt genetic testing; the diagnosis cannot be made on clinical grounds alone given phenotypic overlap with X-linked IFAP1, BRESHECK syndrome, and hereditary mucoepithelial dysplasia (which shares a "common clinical spectrum" with IFAP per Irurzun et al., PMID referenced in search results).
• Genetic testing: Whole-exome sequencing (WES) is the diagnostic modality used in essentially all reported IFAP2 cases (founding cohort and subsequent case reports), given the absence of a clinically distinguishing feature that would point specifically to SREBF1 over MBTPS2. Targeted Sanger sequencing of SREBF1 (particularly the residue 527–530 hotspot) can be used for rapid confirmation/segregation testing once a proband variant is known, as performed via parental Sanger validation in the Ambarchyan et al. case. No specific gene panel name was identified in available sources; ichthyosis/genodermatosis NGS panels including SREBF1 and MBTPS2 would be the practical approach.
• Biopsy/histopathology: Scalp skin biopsy showing orthohyperkeratosis, acanthosis, dilated infundibulum filled with keratotic plugs, and perivascular lymphocytic infiltration in the superficial dermis (documented in the founding cohort's Family 1 patient).
• Hair shaft microscopy: Scanning electron microscopy showing cuticle warping/detachment and trichorrhexis nodosa is a useful ancillary diagnostic clue.
• Ophthalmologic exam: Slit-lamp evaluation for meibomian gland dysfunction, punctate corneal epithelial defects, corneal pannus, and cataract; meibum lipidomic analysis has been explored as a research tool linking the ocular phenotype directly to the molecular lesion (PMID: 40778116).
• Differential diagnosis: X-linked IFAP syndrome 1 (MBTPS2, distinguishable definitively only by molecular testing, though X-linked inheritance pattern/male predominance and more severe multisystem involvement in BRESHECK-spectrum cases are clues); hereditary mucoepithelial dysplasia; other syndromic ichthyoses (e.g., Netherton syndrome, KID syndrome); congenital atrichia with papular lesions.
• Screening: No population or newborn screening program exists for this ultra-rare dominant disorder; prenatal/preimplantation testing could be offered in families with a known pathogenic variant, given the dominant inheritance and documented vertical transmission.

Suggested NCIT/LOINC/diagnostic-workflow terms: NCIT:C15709 (Genetic Testing); a WES-based diagnostic term is most appropriate given no single confirmatory lab biomarker exists.

11. Outcome/Prognosis

• Survival/mortality: No mortality has been reported to be directly attributable to IFAP2; documented adult survivors (mothers aged 47–48 in the founding cohort) indicate a normal or near-normal life expectancy, in contrast to some MBTPS2-BRESHECK-spectrum presentations which can be more severe.
• Morbidity: Primarily visual (progressive corneal disease, cataract, if unmanaged) and dermatologic/psychosocial (chronic scaling, alopecia).
• Complications: Progressive corneal opacification and vision loss are the most significant reported complication if ocular disease is inadequately managed; recurrent corneal epithelial breakdown risks secondary infection.
• Recovery potential: The underlying molecular lesion is not correctable with current therapy; symptomatic treatments can improve but not normalize skin and corneal findings (see Treatment, below).
• Prognostic factors: No formal prognostic biomarkers have been established; phenotype severity does not clearly track with a specific variant beyond the general observation that the p.Arg527Cys hotspot variant produces a broad severity spectrum and at least one distinct variant (c.1670G>A) produces an atypical, photophobia-negative, psoriasiform-predominant course.
• Quality-of-life data: No disease-specific quality-of-life instrument data identified in the literature — a notable data gap for a chronic, visible, and vision-threatening condition.

12. Treatment

No disease-modifying or curative therapy exists; management is symptomatic and multidisciplinary (dermatology + ophthalmology), extrapolated largely from broader IFAP-syndrome and ichthyosis management literature (much of it published for IFAP1/MBTPS2 cases, but applied analogously to IFAP2):

• Pharmacotherapy — systemic retinoids: Oral acitretin (dosing reported in the range ~0.3–1 mg/kg/day) produces moderate improvement in cutaneous hyperkeratosis and corneal erosions but does not improve alopecia or photophobia (PMID: 16268889, and corroborated in subsequent reviews). NCIT suggestion: NCIT:C61004 (Acitretin) as therapeutic_agent under a treatment_term of NCIT:C15986 (Pharmacotherapy).
• Topical therapy: Emollients and keratolytics for symptomatic scale reduction; topical retinoids are generally poorly tolerated due to irritation.
• Ocular management: Intensive ocular surface lubrication is the mainstay for corneal protection; prophylactic topical antibiotics are used to reduce infection risk from epithelial breakdown; topical corticosteroids are generally ineffective for the corneal complications. In severe, recalcitrant corneal epithelial defects, bilateral lateral tarsorrhaphy has been performed (reported as early as 7 months of age in a severe case) to protect the ocular surface. NCIT suggestion: NCIT:C15329 (Surgical Procedure) for tarsorrhaphy.
• Meibomian gland-directed therapy: Given the mechanistic link between defective SREBP1-driven lipogenesis and abnormal meibum composition (PMID: 40778116), lid hygiene and warm compresses (standard meibomian gland dysfunction management) are a rational, though not yet formally trial-tested, adjunct.
• Experimental/theoretical approaches: The founding molecular paper (PMID: 32497488) proposes, as an untested theoretical strategy, topical cholesterol or lipid supplementation to bypass the SREBP1 lipogenic defect and stimulate hair growth/improve skin and ocular abnormalities, drawing an analogy to related lipid-synthesis-disorder case reports and mouse studies — this has not been clinically validated in IFAP2 patients and represents an open therapeutic research question.
• No gene therapy, RNA-based therapy, cell therapy, or targeted molecular therapy has been reported or is in clinical trials for IFAP2 specifically (searched ClinicalTrials.gov equivalent terms — none identified; this is a clinical-trial data gap consistent with the disorder's extreme rarity).
• Supportive/rehabilitative care: Genetic counseling is indicated given autosomal dominant inheritance and documented vertical transmission; psychosocial support for visible skin/hair differences is a reasonable component of comprehensive care, though not specifically studied in this population.

13. Prevention

• Primary prevention: Not applicable — this is a germline, largely de novo dominant condition with no known modifiable risk factor.
• Secondary prevention: Early ophthalmologic surveillance and aggressive management of corneal epithelial defects to prevent progression to vision-threatening pannus/opacification is the most actionable "secondary prevention" measure identified in the literature.
• Genetic counseling: Recommended for identified families given autosomal dominant inheritance, ~50% transmission risk to offspring of an affected parent, and the observed compatibility of the condition with reproduction; prenatal or preimplantation genetic testing could be offered once a familial variant is known.
• Screening: No population-level or newborn screening program exists.
• Public health/environmental interventions: Not applicable — no environmental risk factor has been identified to intervene upon.

14. Other Species / Natural Disease

• No naturally occurring IFAP-syndrome-like disease in non-human species (companion animals, livestock, or wildlife) has been identified in the literature searched (no OMIA entry found for an SREBF1-linked ichthyosis/atrichia/photophobia phenotype).
• Orthologous gene: Srebf1 is highly conserved across vertebrates (mouse Srebf1, MGI:107606; NCBI Gene). Comparative biology relevance is limited to the conserved SREBP-SCAP-Insig sterol-sensing pathway rather than a documented natural veterinary disease counterpart.
• Zoonotic potential: Not applicable (non-infectious, monogenic disorder).

15. Model Organisms

• Mouse: Complete Srebf1 germline knockout in mice causes substantial embryonic lethality (reported ~50–85%), reflecting the gene's essential role in lipid metabolism during development; this severe embryonic phenotype has limited the use of full knockouts to model the human heterozygous IFAP2 phenotype, and no published mouse model specifically recapitulating the IFAP2 hotspot missense variants (p.Arg527Cys etc.) was identified in the literature searched — a clear model-system gap (candidate HUMAN_MODEL_MISMATCH consideration for future curation: no animal model has yet been shown to recapitulate the specific S1P-cleavage-resistant IFAP2 allele).
• Related pathway models: Tissue-specific/conditional Srebf1 or SREBP-pathway perturbation studies exist for skin/sebaceous-gland lipid biology more broadly (e.g., glycerol kinase 5 (GK5)-mediated skin-specific regulation of SREBP processing and lipid biosynthesis, PNAS 2017) and support the general mechanistic link between SREBP signaling and epidermal/sebaceous lipogenesis invoked to explain IFAP2 pathophysiology, but these are pathway-level models, not IFAP2-specific disease models.
• Cellular models: The founding study's own functional work (HEK293 transfection with mutant SREBF1 constructs) constitutes the principal "model system" evidence for IFAP2 — an in vitro, heterologous overexpression system demonstrating loss of S1P-mediated cleavage, nuclear translocation, and SRE-driven transcriptional activity for each of the three founding variants (PMID: 32497488). This is strong direct mechanistic evidence but is not a whole-organism/tissue-context model, and translational fidelity to intact human skin/hair-follicle/meibomian-gland biology has not been independently confirmed beyond the patient-derived scalp-skin RNA-seq and histopathology data described above.
• Resources: MGI:107606 (mouse Srebf1); International Mouse Phenotyping Consortium (IMPC) entry for Srebf1 (mousephenotype.org) — reports embryonic-lethal/subviable status precluding standard adult phenotyping pipelines for the null allele.

Summary of Key Evidence Sources

Notable data gaps for KB curation: no formal prevalence estimate; no IFAP2-specific animal model; no disease-specific quality-of-life instrument data; no completed or ongoing clinical trials (NCT) specific to IFAP2; mechanistic link between the apoptosis finding and hyperkeratosis/hypotrichosis phenotype is explicitly stated by the primary authors as associative rather than causally demonstrated; the c.1670G>A "atypical/psoriasiform" phenotype's relationship to the canonical lipogenic-deficiency mechanism is unresolved and would be a good candidate for a HUMAN_MODEL_MISMATCH/knowledge-gap discussion node if curated into dismech.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0007431 (2 mentions) - the report calls it "Lamellar-ichthyosis-like scaling (alternative presentation)"; HP calls it Congenital ichthyosiform erythroderma
• HP:0100025 (1 mention) - the report calls it "angular cheilitis"; HP calls it Overfriendliness
• HP:0002298 (1 mention) - the report calls it "atrichia"; HP calls it Absent hair
• HP:0000966 (1 mention) - the report calls it "Moderate–severe hypotrichosis (sparse, thin hair)"; HP calls it Hypohidrosis
• HP:0011364 (1 mention) - the report calls it "hair shaft abnormality"; HP calls it White hair
• HP:0012207 (1 mention) - the report calls it "Trichorrhexis nodosa (hair shaft defect on SEM)"; HP calls it Reduced sperm motility
• HP:0100708 (1 mention) - the report calls it "Meibomian gland dysfunction"; HP calls it Abnormal microglia morphology
• HP:0008058 (1 mention) - the report calls it "Punctate corneal epithelial defects"; HP calls it Aplasia/Hypoplasia of the optic nerve
• GO:0045543 (1 mention) - the report calls it "regulation of fatty acid biosynthetic process"; GO calls it gibberellin 2-beta-dioxygenase activity
• CL:1000428 (1 mention) - the report calls it "outer root sheath cell of hair follicle, if available"; CL calls it stem cell of epidermis
• CL:0002261 (1 mention) - the report calls it "sebaceous gland cell, for meibocyte-analog reasoning"; CL calls it endothelial cell of viscerocranial mucosa
• UBERON:0006238 (1 mention) - the report calls it "meibomian gland"; UBERON calls it future brain
• NCIT:C61004 (1 mention) - the report calls it "Acitretin"; NCIT calls it Tablet for Solution Dosage Form

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• HP:0100637 (obsolete Neoplasia of the nose) (1 mention) - replaced by HP:0012720
• GO:0044255 (obsolete cellular lipid metabolic process) (1 mention) - replaced by GO:0006629

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• MONDO:0100212 (1 mention) - the report calls it "IFAP syndrome, general"; MONDO calls it IFAP syndrome
• HP:0007957 (1 mention) - the report calls it "corneal neovascularization"; HP calls it Corneal opacity, and lists "Corneal opacities" among its other names
• HP:0000518 (1 mention) - the report calls it "Cataract (complicated)"; HP calls it Cataract
• GO:0044255 (1 mention) - the report calls it "cellular lipid metabolic process"; GO calls it obsolete cellular lipid metabolic process
• GO:0005783 (1 mention) - the report calls it "endoplasmic reticulum, site of SCAP-SREBP1 pre-processing"; GO calls it endoplasmic reticulum

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: MGI.